Building bridges in cancer: Mismatch repair and microsatellite instability

American Journal of Dermatopathology

Volumn 24, Issue 1, 2002, Pages 76-81

  Hussein, Mahmoud R ^a   Wood, Gary S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

High frequency microsatellite instability; Low frequency microsatellite instability; Microsatellite instability; Microsatellite stable; Mismatch repair

Indexed keywords

DNA;

CANCER CLASSIFICATION; CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC ANALYSIS; GENETIC STABILITY; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN CANCER;

BASE PAIR MISMATCH; DNA, NEOPLASM; MICROSATELLITE REPEATS; MUTATION, MISSENSE; SKIN NEOPLASMS;

EID: 0036161890     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200202000-00016     Document Type: Review

References (96)

1. Clues to the pathogenesis of familial colorectal cancer
2. Microsatellite polymorphism linkage map of human chromosome 13q
3. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile
4. Microsatellite instability in bladder cancer
5. Frequent microsatellite instability in primary small cell lung cancer
6. Genetic instability of microsatellite sequences in many non-small cell lung carcinomas
7. Mutation of a mutL homolog in hereditary colon cancer
8. DNA loop repair by human cell extracts
9. Hypermutability and mismatch repair deficiency in RER+ tumor cells
10. A genetic model of melanoma tumorigenesis based on allelic losses
11. Microsatellite instability in primary and metastatic melanoma
12. Microsatellite alterations as clonal markers for the detection of human cancer
13. Application of microsatellite alteration of urine sediment in the early diagnosis of bladder cancer [in Chinese]
14. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis
15. Mismatch repair defects in human carcinogenesis
16. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
17. Genetic and antigenic characterization of a serotype G6 human rotavirus isolated in Melbourne, Australia
18. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells
19. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
20. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer
21. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
22. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes
23. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
24. Expression of five selected human mismatch repair genes simultaneously detected in normal and cancer cell lines by a nonradioactive multiplex reverse transcription-polymerase chain reaction
25. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability
26. Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer
27. Microsatellite instability in patients with multiple primary cancers of the gastrointestinal tract
28. Assessment of markers for the identification of microsatellite instability phenotype in gastric neoplasms
29. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences
30. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability
31. Mismatch repair and microsatellite instability in esophageal cancer cells
32. Microsatellite instability is associated with genetic alteration but not with low levels of expression of the human mismatch repair proteins hMSH2 and hMLH1
33. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues
34. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas
35. Microsatellite instability (MSI) in non-colonic, non-HNPCC tumors: "Instable" evidence?
36. Mismatch repair, genetic stability, and cancer
37. Genetic instability occurs in the majority of young patients with colorectal cancer
38. Assessment of microsatellite instability in a cell line from a patient with xeroderma pigmentosum variant
39. Microsatellite instability: New aspects in the carcinogenesis of colorectal carcinoma
40. Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principal involvement of hMLH1
41. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability
42. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1
43. Microsatellite instability and mismatch-repair protein expression in hereditary and sporadic colorectal carcinogenesis
44. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
45. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability
46. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
47. Origin of microsatellite instability in gastric cancer
48. HMSH6 alterations in patients with microsatellite instability-low colorectal cancer
49. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
50. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi
51. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas
52. Microsatellite instability in human melanocytic skin tumors: An incidental finding or a pathogenetic mechanism?
53. Requirement of the yeast MSH3 and MSH6 genes for MSH2-dependent genomic stability
54. Mutations of GTBP in genetically unstable cells
55. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair
56. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas
57. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2
58. Immunohistochemical analysis of DNA "mismatch-repair" enzyme human Mut-S-Homologon-2 in ovarian carcinomas
59. DNA repair and aging in basal cell carcinoma: A molecular epidemiology study
60. DNA damage, mutation and fine structure DNA repair in aging
61. Mutation frequency in human blood cells increases with age
62. The effect of donor age on the processing of UV-damaged DNA by cultured human cells: Reduced DNA repair capacity and increased DNA mutability
63. A cell cycle regulator potentially involved in genesis of many tumor types
64. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
65. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
66. Complex structure and regulation of the P16 (MTS1) locus
67. Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
68. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: Association with DNA replication error and shorter survival
69. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas
70. Hypermethylation of the p16 gene in nasopharyngeal carcinoma
71. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non- Hodgkin's lymphoma
72. Frequent hypermethylation of p16 and p15 genes in multiple myeloma
73. The MTS1 gene is frequently mutated in primary human esophageal tumors
74. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression
75. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines
76. The molecular biology of esophageal carcinoma
77. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population
78. Microsatellite instability and other molecular abnormalities in childhood acute lymphoblastic leukaemia
79. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes
80. Creation of psoriatic plaques: The ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint
81. Cellular senescence and cancer
82. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
83. Replicative senescence as a barrier to human cancer
84. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
85. Evolutionary conservation of the biochemical properties of p53: Specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70
86. Cancer. A death in the life of p53
87. Cancer. p53, guardian of the genome
88. Overexpression of p53 protein associated with proliferative activity as evaluated by Ki-67 immunostaining in well-differentiated squamous cell carcinoma of the skin
89. p53 expression in Bowen's disease and in microinvasive squamous cell carcinoma of the skin
90. Over-expression of p53 protein in squamous cell carcinoma of the skin
91. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma
92. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
93. Cancer. Death and methylation
94. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
95. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
96. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma